Shopping Cart
Remove All
Your shopping cart is currently empty
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | - | In Stock | |
| 5 mg | $538 | - | In Stock | |
| 10 mg | $872 | - | In Stock | |
| 25 mg | $1,290 | - | In Stock | |
| 50 mg | $1,730 | - | In Stock |
| Description | LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer. |
| Synonyms | hLIV22 |
| Reactivity | Human |
| Verified Activity | Immobilized Human LIV-1 Protein at 2 μg/mL (30 μL/well) can bind Ladiratuzumab. The EC50 is 5.145 ng/mL. ![]() |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | LIV-1/SLC39A6 |
| Molecular Weight | 146.1 kDa |
| Cas No. | 1629760-28-6 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.